Program
dabogratinib
Also written as “Dabogratinib (TYRA-300) 60mg”, “Dabogratinib (TYRA-300) 80mg” and “TYRA-300 60mg”.
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Achondroplasia · Carcinoma, Transitional Cell, led by Tyra Biosciences.
Furthest: phase 2, since Sep 6, 20225 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tyra Biosciences | 55 open or running | phase 2since Sep 6, 2022 | Sep 6, 2022 | Nov 2026phase 2 · NCT05544552 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 6, 2022First study: phase 2 study in Carcinoma, Transitional CellFirst studyNCT05544552 · 310 enrolled · United States, Australia, France and more
- Aug 17, 2023Phase 1 study in HealthyNCT06006702 · 60 enrolled · Australia
- Jan 29, 2025Phase 2 study in AchondroplasiaNCT06842355 · 92 planned · United States, Australia, Canada and more
- Apr 25, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06995677 · 90 planned · United States, Australia, Italy and more
- Nov 19, 2025Phase 2 study in Low Grade Upper Tract Urothelial CarcinomaNCT07265947 · 285 planned · United States, France, Israel and more
Ahead
- Nov 2026Primary completion: phase 2 study in Carcinoma, Transitional CellNCT05544552
- Feb 2028Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06995677
- Jan 2030Primary completion: phase 2 study in AchondroplasiaNCT06842355
- Oct 2030Primary completion: phase 2 study in Low Grade Upper Tract Urothelial CarcinomaNCT07265947
TargetBeta
FGFR3 →read by rule
“An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 3 (FGFR3), ”NCIt, by rule
Other programs on FGFR3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| masitinibrule | AB Science | phase 3 | 38 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| pemigatinibrule | Incyte | phase 3 | 16 |
| futibatinibrule | Otsuka | phase 3 | 10 |
| vepugratinibrule | Eli Lilly | phase 3 | 5 |
| FGFR3/4 Inhibitor TYRA-430rule | Tyra Biosciences | phase 1 | 1 |
| Anti-FGFR3 Antibody-drug Conjugate BHV-1530rule | biohaven-therapeutics-ltd | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07265947Low Grade Upper Tract Urothelial Carcinoma · United States, France, Israel and more | 2 | Recruiting | Oct 2030 | 285 |
| NCT06995677Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Italy and more | 2 | Recruiting | Feb 2028 | 90 |
| NCT06842355Achondroplasia · United States, Australia, Canada and more | 2 | Recruiting | Jan 2030 | 92 |
| NCT06006702Healthy · Australia | 1 | Active, not recruiting | May 2025 | 60 |
| NCT05544552Carcinoma, Transitional Cell · United States, Australia, France and more | 2 | Active, not recruiting | Nov 2026 | 310 |
How it is read
Names in the registry
- “Dabogratinib (TYRA-300) 60mg”, 1 entry
- “Dabogratinib (TYRA-300) 80mg”, 1 entry
- “TYRA-300 60mg”, 1 entry
- “TYRA-300 50mg”, 1 entry
- “TYRA-300 Dose 70 mg”, 1 entry
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 1 study
- Achondroplasia, 1 study
- Carcinoma, Transitional Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.